Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 18 studies | 38% ± 16% | |
intestine | 13 studies | 35% ± 14% | |
peripheral blood | 11 studies | 23% ± 5% | |
kidney | 9 studies | 32% ± 11% | |
brain | 7 studies | 29% ± 7% | |
eye | 6 studies | 33% ± 14% | |
liver | 5 studies | 31% ± 15% | |
pancreas | 4 studies | 63% ± 20% | |
lymph node | 4 studies | 32% ± 16% | |
breast | 4 studies | 33% ± 2% | |
bone marrow | 3 studies | 22% ± 7% | |
adrenal gland | 3 studies | 25% ± 3% | |
prostate | 3 studies | 35% ± 7% | |
thymus | 3 studies | 34% ± 9% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
bladder | 100% | 2590.33 | 21 / 21 | 42% | 0.70 | 213 / 504 |
pancreas | 100% | 3112.83 | 328 / 328 | 35% | 0.57 | 63 / 178 |
ovary | 100% | 2310.66 | 180 / 180 | 34% | 0.50 | 146 / 430 |
intestine | 100% | 2773.13 | 966 / 966 | 32% | 0.60 | 168 / 527 |
thymus | 100% | 4909.73 | 653 / 653 | 31% | 0.45 | 186 / 605 |
uterus | 100% | 2768.50 | 170 / 170 | 26% | 0.37 | 118 / 459 |
stomach | 100% | 2371.60 | 359 / 359 | 21% | 0.45 | 59 / 286 |
prostate | 100% | 3170.48 | 245 / 245 | 16% | 0.22 | 80 / 502 |
lung | 100% | 2290.36 | 576 / 578 | 14% | 0.20 | 167 / 1155 |
kidney | 100% | 3521.37 | 89 / 89 | 11% | 0.16 | 97 / 901 |
esophagus | 100% | 2256.91 | 1445 / 1445 | 8% | 0.09 | 14 / 183 |
breast | 100% | 2014.22 | 459 / 459 | 7% | 0.11 | 79 / 1118 |
adrenal gland | 100% | 3383.23 | 258 / 258 | 6% | 0.08 | 13 / 230 |
skin | 100% | 2087.88 | 1808 / 1809 | 4% | 0.06 | 21 / 472 |
brain | 100% | 2738.04 | 2639 / 2642 | 4% | 0.06 | 29 / 705 |
liver | 100% | 3299.58 | 226 / 226 | 4% | 0.05 | 16 / 406 |
spleen | 100% | 2505.72 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 2.31 | 1 / 1 |
adipose | 100% | 1953.24 | 1203 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 2714.77 | 1333 / 1335 | 0% | 0 | 0 / 0 |
heart | 99% | 1908.78 | 854 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 86% | 982.92 | 803 / 929 | 0% | 0 | 0 / 0 |
muscle | 81% | 633.48 | 652 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 21% | 0.27 | 6 / 29 |
tonsil | 0% | 0 | 0 / 0 | 13% | 0.15 | 6 / 45 |
eye | 0% | 0 | 0 / 0 | 13% | 0.15 | 10 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0061077 | Biological process | chaperone-mediated protein folding |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0005528 | Molecular function | FK506 binding |
GO_0005515 | Molecular function | protein binding |
GO_0003755 | Molecular function | peptidyl-prolyl cis-trans isomerase activity |
Gene name | FKBP2 |
Protein name | Peptidyl-prolyl cis-trans isomerase FKBP2 (PPIase FKBP2) (EC 5.2.1.8) (13 kDa FK506-binding protein) (13 kDa FKBP) (FKBP-13) (FK506-binding protein 2) (FKBP-2) (Immunophilin FKBP13) (Rotamase) peptidylprolyl isomerase (EC 5.2.1.8) |
Synonyms | hCG_21364 FKBP13 |
Description | FUNCTION: PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides. |
Accessions | ENST00000449942.6 ENST00000309366.9 F5H0N4 ENST00000652094.1 ENST00000535135.7 Q53XJ5 A0A494C1N0 P26885 |